V-114
Comparing speech biomarkers with standard neurocognitive indicators of Alzheimer’s dementia
Ivan Caro1,2, Gonzalo Pérez1,2,3, Joaquín Valdés Bize4, Joaquín Ponferrada1, Franco Ferrante1,2,3, Alejandro Sosa Welford1, Lara Gauder5, Luciana Ferrer5, Agustín Ibañez1,2,6, 7, Andrea Slachevsky8,9,10, 11, Adolfo M. García1,7, 12
  1. Cognitive Neuroscience Center (CNC), Universidad de San Andrés, Buenos Aires, Argentina
  2. National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
  3. School of Engineering, University of Buenos Aires, Buenos Aires, Argentina
  4. Department of Psychiatry, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
  5. Instituto de Investigación en Ciencias de la Computación (ICC), CONICET-UBA, Argentina, Departamento de Computación, Faculty of Exact and Natural Sciences, University of Buenos Aires (UBA), Argentina.
  6. atin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez, Santiago, Chile
  7. lobal Brain Health Institute, University of California San Francisco, San Francisco, California, USA; and Trinity College Dublin, Dublin, Ireland
  8. Neuropsychology and Clinical Neuroscience Laboratory, Physiopathology Department, ICBM, Neurosciences Department, Faculty of Medicine, University of Chile, Santiago, Chile
  9. Gerosciences Center for Brain Health and Metabolism, Santiago, Chile
  10. Memory and Neuropsychiatric Clinic (CMYN) Neurology Department, Hospital del Salvador & University of Chile, Santiago, Chile
  11. Servicio de Neurología, Departamento de Medicina, Clínica Alemana-Universidad del Desarrollo, Santiago, Chile
  12. Departamento de Lingüística y Literatura, Facultad de Humanidades, Universidad de Santiago de Chile, Santiago, Chile
Presenting Author:
Ivan Caro
icaro@udesa.edu.ar
A novel digital approach to detecting scalable markers of Alzheimer’s dementia (AD) involves the automated analysis of word properties (WP), enabling both disease detection and prediction of cognitive performance and associated brain correlates. Yet, uncertainty persists regarding the clinical value of WP markers, since no study has compared their discriminative power with standard cognitive and neural measures. We recruited 33 patients with AD and 33 healthy controls, who completed verbal fluency tasks, cognitive tests, and MRI/fMRI scans. Separate machine learning classifiers were trained using (i) WP features from the fluency tasks, (ii) MMSE score, (iii) TMT and digit span scores, (iv) MRI measures, and (v) fMRI measures. The best-performing model for each feature set was evaluated based on mean AUC. WP classification performance (AUC = .85) was comparable (p > .3) to MMSE (AUC = .89), TMT/Digit (AUC = .78), and MRI (AUC = .89) features, and superior to fMRI features (AUC = .65, p < .05). The most important WP feature was word frequency, which showed a negative correlation with the volume of right prefrontal regions involved in executive processing. Our speech approach can identify AD with performance comparable to gold-standard measures, driven by features linked to brain regions implicated in cognitive symptoms of AD. Overall, WP analyses seem non-inferior to standard diagnostic measures, highlighting their potential as a scalable and low-cost tool for dementia